Tag Archives: Nasdaq Biotech Index

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector. Overall, the S&P500 was flat for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Nasdaq Biotech Index re-ranking for next Monday

Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched Nasdaq Biotechnology Index (NBI). This Monday (May 23rd), six companies will be added to the Nasdaq Biotech index and two will be removed. The additions are Achillion Pharmaceuticals (ACHN), AVEO Pharmaceuticals (AVEO), Columbia Laboratories (CBRX), ISTA Pharmaceuticals (ISTA), Pacific Biosciences (PACB) and Zalicus (ZLCS). The two companies to be removed from the NBI are Biodel (BIOD) and China Sky One Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech Sector Performance Update 1H 2010

In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , ,